Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans

In human nonvitrectomized eyes, the aqueous half-life of 0.5 mg intravitreally injected ranibizumab is 7.19 days, slightly shorter than the half-life of 9.82 days previously determined for bevacizumab by comparable methods.